KEIO RESEARCHERS INFORMATION SYSTEM

Message from the Faculty Member 【 Display / hide 】

Message from the Faculty Member 【 Display / hide 】

• 自分のこれまでの経験では、実験がうまくいってもそこから得られるものは何もありません。失敗して、原因をあれこれ考えることで自分が知らなかった知見を得たり、新しい発見をしたりします。したがって、多くのことに果敢にチェレンジしてたくさんの失敗を重ねて欲しいと思います。失敗が必ず皆さんの糧になります。

Other Disclosed Information 【 Display / hide 】

Other Disclosed Information 【 Display / hide 】

• Metabolomics, Analytical Chemistry

Career 【 Display / hide 】

Career 【 Display / hide 】

• 1984.04

  -

  1992.03

  Application Chemist, Yokogawa Corp.

• 1992.04

  -

  2001.03

  Yokogawa Analytical Systems Inc.

• 2001.04

  -

  2002.03

  University of the Ryukyus, Visiting Professor

• 2001.04

  -

  2005.03

  Faculty of Environmental Information/ Institute for Advanced Biosciences, Associate Professor

• 2003.07

  -

  2010.03

  Human Metabolome Technologies Inc., Director

display all >>

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 1980.04

  -

  1984.03

  Keio University, Faculty of Engineering, Applied Chemistry

  University, Graduated

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• Ph.D., Toyohashi University of Technology, Dissertation, 2000.03

Research Themes 【 Display / hide 】

Research Themes 【 Display / hide 】

• 枯草菌、大腸菌、酵母等のバクテリアからイネやマウスの組織、ヒトの血液、尿、赤血球、ガン細胞等のあらゆる生物種の細胞内全代謝物質（メタボローム）の測定法, 

  　

Books 【 Display / hide 】

Books 【 Display / hide 】

• Advances in Microscale Electro-and Liquid Phase-Based Separation Techniques

  El Rassi, Z., Ed. (Soga, T., contribution for Chapter Chapter 9), Elsevier Inc., 2026.03

  Scope: Chapter 9: “Capillary electrophoresis-mass spectrometry”,  Contact page： pp.279-294

  　View Summary

  Capillary electrophoresis-mass spectrometry (CE-MS) has gained a great deal of attention as a powerful tool for the analysis of charged compounds. This approach offers high-resolution, high-sensitivity, and wide versatility. Over the past three decades, several CE-MS methods have been developed and have made significant advances in analytical chemistry. In this chapter, the general strategies and principles of CE-MS methods will be discussed, including CE separation modes, interface techniques, mass spectrometry, new techniques to increase the throughput capability of CE-MS analysis, metabolomics, and even single-cell analysis, which has received much attention in recent years. Finally, general conclusions and perspectives are provided.

  • Access to Document (DOI)

• Amino Acid Analysis : Methods and Protocols

  Alterman M.Ed., (Hirayama, A., Ikeda, S., Sato, A., Soga, T., contribution for Chapter 23）, Humana Press, 2019.07

  Scope: Chapter 23: Amino Acid Analysis by Capillary Electrophoresis-Mass Spectrometry,  Contact page： 307-313

  　View Summary

  Capillary electrophoresis-mass spectrometry (CE-MS) has been developed as a powerful tool in the analysis of charged compounds. To simultaneously analyze free amino acids, an electrolyte with low pH was used to positively charge all of the amino acids. In this condition, all protonated amino acids migrated toward the cathode in CE and then were sensitively and selectively detected by MS. This method is simple, rapid, and selective and could readily be applied to the analysis of free amino acids in various samples. In this chapter, the detailed procedure to analyze amino acids using CE-tandem mass spectrometry (MS/MS) is described.

• Oceanography Challenges to Future Earth : Human and Natural Impacts on our Seas

  Komatsu, T., Ceccaldi, H-J., Yoshida, J., Prouzet, P., Henocque, Y. Ed., (Nakano, T., Shirakawa, H., Yeo, G., Devlin, R.H., Soga, T., contribution for Part IV ), Springer, 2019.02,  Page： 430

  Scope: Part IV Innovative Research: Metabolome profiling of growth hormone transgenic coho salmon by capillary electrophoresis time-of-flight mass spectrometry,  Contact page： 223-234

• Capillary Electrophoresis-Mass Spectrometry for Metabolomics

  Ramautar R. Ed., (Hirayama A, Soga T. contribution for CHAPTER 7), The Royal Society of Chemistry, 2018.07,  Page： 300

  Scope: CHAPTER 7: CE-MS for anionic and cationic metabolic profiling: system optimization and applications,  Contact page： 134-160

• ONCO-METABOLOMICS; A NEW CLUE TO UNDERSTAND CARCINOGENESIS, CANCER BIOLOGY AND TO DEVELOP NOVEL DIAGNOSTICS AND THERAPEUTICS

  Esmi, H., Mak, T.W., Soga, T., Suematsu, M.,Mori, M. Ed, Princess Takamatsu Cancer Research Fund, 2016.04

display all >>

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• 2,3-Pyridinedicarboxylate Is Associated with Shorter Recurrence-Free Survival in Patients with Hypopharyngeal Squamous Cell Carcinoma

  Takase, H., Fujisawa, T., Hayashi, R., Makinoshima, H., Suzuki, Y., Soga, T., Fujii, S.

  Pathobiology 93 ( 2 ) 72 - 86 2026.06

  Research paper (scientific journal), Joint Work, Accepted,  ISSN  10152008

  　View Summary

  Introduction: Metabolites are associated with the biology of cancer; however, no metabolites related to prognosis have been identified in head and neck cancer. This study aimed to identify metabolites associated with prognosis in patients with hypopharyngeal squamous cell carcinoma (HPSCC).
  
  Methods: Fifty-two patients who underwent surgery for HPSCC were included and randomly divided into test and validation cohorts of 26 patients each for further metabolome analysis using capillary electrophoresis/mass spectrometry on tumor and non-tumor tissues of the hypopharynx. Twenty-two patients who received adjuvant therapy after surgery were included. The receiver operating characteristic (ROC) and univariate and multivariate analyses were used to explore the relationship between recurrence-free survival (RFS), clinicopathological factors, and differentiated metabolites.
  
  Results: ROC analysis revealed six metabolites significantly associated with RFS in both cohorts, and multivariate analysis indicated that 2,3-pyridinedicarboxylate was a significantly independent poorer prognostic factor in the cohorts including patients with HPSCC without any adjuvant therapies (p = 0.017).
  
  Conclusion: 2,3-Pyridinedicarboxylate, involved in NAD+ metabolism and genomic stability, suggests the possibility of developing molecular-targeted drugs for the production of metabolites related to prognosis. This study identifies novel prognostic metabolites and their associated metabolic pathways in HPSCC, highlighting potential therapeutic targets for treatment.
  
  Keywords: 2,3-Pyridinedicarboxylate; Hypopharyngeal squamous cell carcinoma; Metabolites; Recurrence-free survival.

  • Access to Document (DOI)

• Paired tumor–normal metabolomic profiling reveals alterations in choline phospholipid precursor metabolism in biliary tract cancer

  Suto, H., Kumamoto, K., Nagao, M., Furuichi, Y., Fuke, T., Matsukawa, H., Ando, Y., Oshima, M., Kobayashi, K., Kobara, H., Soga, T., Okano, K.

  J. Gastroenterol. online 2026.06

  Research paper (scientific journal), Joint Work

  　View Summary

  Background: The metabolic landscape of biliary tract cancer (BTC) remains poorly characterized. This study aimed to identify tumor-specific metabolic alterations in BTC using paired tumor and adjacent normal tissues.
  
  Methods: Metabolomic profiling was performed on paired tumor and adjacent normal tissues from 71 patients with BTC using capillary electrophoresis time-of-flight mass spectrometry. Differential metabolites were identified using paired statistical analysis with false discovery rate correction. Pathway enrichment analysis was conducted using the Kyoto Encyclopedia of Genes and Genomes database.
  
  Results: Seventeen metabolites were significantly altered between tumor and normal tissues. Pathway analysis identified glycerophospholipid metabolism as the most enriched pathway, driven by water-soluble precursor and intermediate metabolites, including phosphorylcholine, CDP-choline, and ethanolamine phosphate. Hierarchical clustering demonstrated partially distinct metabolic patterns between tumor and normal tissues, with substantial inter-sample variability observed among tumor samples. Metabolites related to amino sugar and nucleotide sugar metabolism were also increased in tumor tissues. Additional pathways, including nicotinate and nicotinamide metabolism and arginine and proline metabolism, were also enriched. Principal component analysis showed partial separation between tumor and normal samples, indicating global metabolic differences between the two groups. These findings indicate metabolic alterations across multiple pathways in BTC.
  
  Conclusions: Paired tissue metabolomics revealed coordinated metabolic alterations in BTC involving choline phospholipid precursor metabolism, amino sugar and nucleotide sugar metabolism, and additional amino acid-related pathways. These results highlight the presence of broad metabolic reprogramming in BTC and underscore the importance of tissue-based metabolomic profiling for characterizing tumor metabolism.
  
  Keywords: Amino acid metabolism; Biliary tract cancer; Choline phospholipid precursor metabolism; Metabolomics; Pathway analysis.

  • Access to Document (DOI)

• An enrichment-based approach to interpreting metabolomic data using differential metabolomic profiles within the iDMET framework

  Matsuta, R., Yamamoto, H., Fukushima, A., Tabata, S., Makinoshima, H., Soga, T., Saito, R., Hyakawa, E.

  BMC Bioinformatics  27 ( 1 ) 131 - 131 2026.06

  Research paper (scientific journal), Joint Work, Accepted

  　View Summary

  BACKGROUND: Pathway enrichment analysis is a crucial method for the biological interpretation of metabolomic data by identifying associations between altered metabolites and biological pathways. However, such traditional approaches often rely on a limited set of predefined metabolic pathways, resulting in a low likelihood of discovering pathways associated with a given metabolic profile. To overcome this limitation, we extended our previously developed iDMET methodology to incorporate a broader range of metabolite sets, including those derived from differential metabolomic profiles. This enhanced approach, termed iDMET+, significantly expands dataset diversity and size, increasing the likelihood of discovering associated metabolite sets for a given metabolic profile, thereby enables more biological insights to be obtained from the metabolic profile. RESULTS: We validated iDMET+ through case studies on three diseases: clear cell renal cell carcinoma, colorectal cancer, and small cell lung cancer. First, using a clear cell renal cell carcinoma study as input, iDMET+ correctly identified another study of the same disease that involved metabolomic analysis. This pair of studies was identified as relevant in our previous iDMET results, showing the consistency between iDMET+ and iDMET. Second, using the metabolomic profile of colorectal cancer as input, iDMET+ identified not only another metabolomic study of the same cancer but, surprisingly, also metabolomic studies on prostate cancer and a high-fat diet. These studies focused on MYC-driven metabolic reprogramming, which was also a major focus of the input study. In both case studies, related studies were enriched because the differential metabolomic profiles of directly associated studies were part of the metabolite set. In contrast, the small cell lung cancer study highlighted limitations in dataset coverage—the absence of directly relevant differential metabolomic profiles resulted in fewer enriched metabolite sets. Nevertheless, the analysis of commonly altered metabolites still yielded some meaningful results. Metabolite alterations associated with inhibition of the purine salvage pathway were observed, suggesting potential involvement in tumor metabolic reprogramming. CONCLUSIONS: These results demonstrate that iDMET+ offers broader biologically relevant information than the conventional pathway-based approaches and has the potential to uncover biologically significant findings by searching across diverse datasets. This work also identifies areas of improvements for iDMET+.

  • Access to Document (DOI)

• Optimization of lens size and ion source parameters for gas chromatography/mass spectrometry-based metabolomics using hydrogen as a carrier gas

  Sato, M., Hayasaka, R., Soga, T., Hirayama, A.

  J. Chromatogr. A  1776   466945 - 466945 2026.06

  Research paper (scientific journal), Joint Work, Accepted

  　View Summary

  Gas chromatography/mass spectrometry (GC/MS) is widely employed in metabolomics owing to its high resolution, reproducibility, and compatibility with volatile and semi-volatile compounds. While helium has traditionally been used as the carrier gas, increasing costs and global shortages have prompted the exploration of hydrogen gas as an alternative. Hydrogen offers faster analysis times and reduced ion source contamination but presents challenges, including ion source reactions, which can change compound fragmentation patterns. To address this, a hydrogen-deactivated electron ionization (EI) source has been developed to minimize undesired chemical interactions and improve spectral integrity. In this study, we systematically evaluated the effect of extraction lens sizes (3, 6, and 9 mm) under hydrogen carrier gas conditions using n-alkane and human metabolomic standard solutions. The hydrogen-deactivated ion source equipped with a 3 mm extraction lens provided superior peak symmetry and the highest signal intensities, with acceptable relative standard deviation (RSD) values (i.e., below 30%). In addition, the reproducible fragmentation patterns as those observed with helium carrier gas were obtained for phosphorylated metabolites. Using this optimized configuration, we applied hydrogen gas-based GC/MS to metabolomic profiling of the human colon cancer cell line HCT116 with mutant isocitrate dehydrogenase 1 (IDH1). Key metabolic alterations, including increased levels of the known biomarker 2-hydroxyglutaric acid, were detected in IDH1-mutant cells compared with wild-type cells. These findings establish hydrogen gas-based GC/MS with a hydrogen-deactivated ion source as a robust and reliable platform for metabolomics, offering an effective alternative to helium-based systems.

  • Access to Document (DOI)

• Polypharmacologic phosphoinositide modulation by FTY720 triggers endomembrane trafficking collapse and metabolic starvation in cancer cells

  Kofuji, S., Sumita, K., Ikeda, Y., Takahashi, Y., Tabata, S., Ito, D., Hirota, Y., Sasaki, M., Kanoh, H., Nakatsu, F., Takeuchi, K., Senda, T., Davis, M.I. Shen, M., Wakimoto, H., Hirayama, A., Soga, T., Simeonov, A., Sasaki, A.T.

  Biochem. Biophys. Res. Commun. 815   153671 - 153671 2026.05

  Research paper (scientific journal), Joint Work, Accepted

  　View Summary

  Phosphoinositides coordinate membrane trafficking and bioenergetic homeostasis, and many tumors rely on elevated phosphoinositide flux to sustain growth. Therapeutic development has largely pursued single-phosphoinositide kinase inhibition, whereas polypharmacologic strategies that perturb the broader network remain underexplored. FTY720 (fingolimod), a clinically approved sphingosine-1-phosphate receptor modulator, shows anti-tumor activity at micromolar concentrations, but its non-canonical mechanisms remain incompletely defined. Building on our work with the structurally related compound KRP203, we show that high-dose FTY720 produces isozyme-divergent modulation across phosphoinositide kinases and biases PIKFYVE activity toward phosphatidylinositol, a pattern we term ASURA (Asymmetric Simultaneous Uncoupling of Related Activities). FTY720 induces vacuolization and endomembrane remodeling in cancer cells, and suppresses macropinocytic ruffling as demonstrated by tracer uptake and scanning ion conductance microscopy analyses. Quantitative metabolomics revealed depletion of intracellular amino acids and ribonucleoside triphosphates, coupled with reduced glycolysis. Concurrently, FTY720 induced extensive rewiring of the hexosamine pathway, nitrogen metabolism, and tricarboxylic acid (TCA)-cycle anaplerosis, along with redox signatures indicating oxidative stress despite a nutrient-replete medium. The metabolites depleted by FTY720 showed extensive, directionally concordant overlap with those depleted by PTEN induction. Patient-derived glioblastoma (GBM) neurospheres were sensitive to FTY720, and co-treatment with a PI3Kα-selective inhibitor augmented growth suppression in U87MG cells. Together, these data support a model in which ASURA-dose FTY720 disrupts phosphoinositide-regulated trafficking and nutrient access, imposing intracellular nutrient stress that culminates in tumor-cell death.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Development of risk prediction models for mild cognitive decline and frailty using metabolomics in a population-based cohort

  Soga, Tomoyoshi

  科学研究費補助金研究成果報告書 2022

• Identifying functional metabolites that decide cell fates of cancer stem cells

  Soga, Tomoyoshi

  科学研究費補助金研究成果報告書 2022

• Development of metabolome profiling method and application to cancer screening

  Soga, Tomoyoshi

  Keio SFC journal (慶應SFC学会)  22 ( 2 ) 320 - 330 2022

  ISSN  13472828

• Metabolome-wide metabolic profiling and non-communicable disease prevention in a population-based cohort study

  Soga, Tomoyoshi

  科学研究費補助金研究成果報告書 2018

• Metabolomics : a new approach to elucidating biosystems

  Soga, Tomoyoshi

  Keio SFC journal (慶應義塾大学湘南藤沢学会)  15 ( 1 ) 64 - 75 2015

  ISSN  13472828

display all >>

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• メタボロームデータの取得

  Soga, T.

  Experimental Medicine (YODOSHA)     86 - 94 2025.03

  Article, review, commentary, editorial, etc. (other), Single Work

• タボローム測手技術の開発と生命科学における意義

  Soga, T.

  SEIKAGAKU (The Japanese Biochemical Society)  96 ( 2 ) 222 - 231 2024.04

  Article, review, commentary, editorial, etc. (other), Single Work

• マルチオミクスによる大腸がんの代謝解析 100年来のがん代謝の謎を解明

  Soga, T.

  CHEMISTRY & CHEMICAL INDUSTRY (The Chemical Society Of Japan)  77 ( 4 ) 268 - 270 2024.04

  Article, review, commentary, editorial, etc. (other), Single Work

• メタボローム解析からマルチオミクスへの展開―マルチオミクスによるがん代謝解析

  Soga, T.

  Experimental Medicine (YODOSHA)  41 ( 15 ) 59(2399) - 67(2407) 2023.09

  Article, review, commentary, editorial, etc. (other), Single Work

• 腫瘍における分岐鎖アミノ酸トランスポーターの役割

  Saito, Y., Soga, T.

  Experimental Medicine (YODOSHA)  40 ( 14 ) 2239 - 2244 2022.08

  Article, review, commentary, editorial, etc. (other), Joint Work

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• Development of CE-MS Metabolomics and Its Application in Cancer

  Tomoyoshi Soga

  [International presentation]  AOMS2025, The 10th Asia-Oceania Mass Spectrometry Conference (ANA InterContinental, Ishigaki island, Okinawa) , 

  2025.06

  , 

  Oral presentation (invited, special), he Mass Spectrometry Society of Japan

• Development of CE-MS Metabolomics and its Application in Cancer

  Tomoyoshi Soga

  [International presentation]  Metabolomics2024, 20th Annual Confereence of the Metabolomics Society (Osaka) , 

  2024.06

• Multi Omics analysis of colorectal cancer metabolism

  [International presentation]  2018 International Meeting on 22nd MDO and 33rd JSSX (Ishikawa Ongakudo, Kanazawa, Ishikawa) , 

  2018.10

  , 

  Oral presentation (invited, special), JSSX (The Japanese Society for the Study of Xenobiotics)、MDO(Microsomes and Drug Oxidations)

• Malti-omics reveals MYC as a master regulator of colorectal cancer metabolism

  SOGA TOMOYOSHI

  [International presentation]  The 1st International Symposium for Trans-Omics (Koshiba Hall, The University of Tokyo, Hongo Campus) , 

  2017.11

  , 

  Oral presentation (invited, special)

• Onco-metabolites and cancer specific metabolic pathways

  SOGA TOMOYOSHI

  [International presentation]  American Association for Cancer Research Annual Meeting 2017, AACR2017, 

  2017.04

  , 

  Oral presentation (invited, special)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• Study of therapeutic approaches to SUCLA2-deleted cancers

  2024.05

  -

  2026.03

  Japan Agency for Medical Research and Development(AMED), Project for Promotion of Cancer Research and Therapeutic Evolution（P-PROMOTE）, Takahashi, Chiaki, Commissioned ｒesearch, Coinvestigator(s)

• Transomic analysis of hybernation and torpor Planned Research

  2023.06

  -

  2026.03

  Ministry of Education,Culture,Sports,Science and Technology(MEXT)/Japan Society for the Promotion of Science(JSPS) , Grant-in-Aid for Transformative Research Areas (A), Kuroda, Shinya, Research grant, Coinvestigator(s)

• 大腸がんにおけるオンコメタボライト・L-2HGの分子基盤の解明

  2022.06

  -

  2025.03

  Ministry of Education,Culture,Sports,Science and Technology(MEXT)/Japan Society for the Promotion of Science(JSPS) , Grant-in-Aid for Scientific Research (C), Tabata, Sho, Other, Coinvestigator(s)

• Spatio-temporal trans-omics analysis of metabolic control mechanisms of multi-cellular organ systems

  2021.10

  -

  2026.03

  Japan Science and Technology Agency(JST), Strategic Basic Research Programs CREST, Kuroda, Shinya, Commissioned ｒesearch, Coinvestigator(s)

• Development of novel therapy targeting SUCLA2 deficiency in advanced prostate cancer

  2021.05

  -

  2023.03

  Japan Agency for Medical Research and Development(AMED), Project for Cancer Research and Therapeutic Evolution (P-CREATE) , Takahashi, C., Commissioned ｒesearch, Coinvestigator(s)

display all >>

Works 【 Display / hide 】

Works 【 Display / hide 】

• 経済産業省主催「バイオ人材育成事業」メタボローム実習講師

  SOGA TOMOYOSHI

  2004.12

  , 

  Other, Joint

• 日経BP社主催バイオファイナンスギルド　メタボローム講座

  SOGA TOMOYOSHI

  2004.08

  , 

  Other, Joint

• キャピラリー電気泳動による無機陰イオン、有機酸、アミノ酸の分析

  そがともよし

  2001.10

  -

  Present

  , 

  Other

  　View Details

  キャピラリー電気泳動法の装置、測定法の原理および様々な測定例を解説した

Intellectual Property Rights, etc. 【 Display / hide 】

Intellectual Property Rights, etc. 【 Display / hide 】

• カテコールアミン類の分析方法(Apparatus and Method for Catecholamine Analysis)

  Date applied： 特願平01-272206  1989.10 

  Date announced： 特開平03-134561  1991.06 

  Date issued： 特許第2833058号  1998.10

  Patent, Single

• 陰イオン性化合物の分析方法(Apparatus and Method for Anion Analysis)

  Date applied： 特願平08-143048  1996.06 

  Date announced： 特開平09-325130  1997.12 

  Date issued： 特許第2912232号  1999.04

  Patent, Single

• キャピラリー電気泳動による陰イオン、アミノ酸、糖類の分析方法及び装置(Capillary Electrophoresis Apparatus and Method for Anions, Amino Acids and Carbohydrate Analysis)

  Date applied： 特願平10-145244  1998.05 

  Date announced： 特開平11-337524  1999.12 

  Date issued： 特許第3038184号  2000.02

  Patent, Single

• 陰イオン性化合物の分離分析方法及び装置(Apparatus and Method for Anion Analysis)

  Date applied： 特願2001-224341  2001.07 

  Date announced： 特開2003-035698  2003.02 

  Date issued： 特許第3341765号  2002.08

  Patent, Single

• 電気泳動測定によるイオン性化合物の移動時間予想方法

  Date applied： 特願2004-245728  2004.08 

  Date announced： 特開2006-064472  2006.03 

  Date issued： 特許第3871689号  2006.10

  Patent, Joint

display all >>

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• Fukuzawa Award

  Soga, T., 2022.11, Keio Univ., メタボローム（細胞内全代謝物質）解析技術の開発と実用化

  Type of Award： Keio commendation etc.

• The 2nd Shigeru Terabe Award

  2015.11,  Division of Electrophoresis, Japan Society for Analytical Chemistry, CE-MSメタボローム測定技術の開発と実用化

  Type of Award： Award from Japanese society, conference, symposium, etc.

• Keio Award

  SOGA Tomoyoshi, 2011.11, Keio University, CE-MSメタボローム測定技術の開発と実用化

  Type of Award： Keio commendation etc.

• 第7回酸化ストレスと肝研究会　奨励賞

  SOGA Tomoyoshi, 2010.11, 酸化ストレスと肝研究会, メタボロミクスによる新規酸化ストレスマーカーの同定と肝臓疾患スクリーニング

  Type of Award： Award from Japanese society, conference, symposium, etc.

  　View Description

  第7回酸化ストレスと肝研究会における研究発表による

• The prize of the chairman of HATSUMEI KYOKAI

  SOGA Tomoyoshi, 2009.07, Japan Institute of Invention and Innovation, Apparatus and Method for Metabolome Analysis

  Type of Award： Other

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• SEMINAR B

  2024

• METABOLOMICS

  2024

• METABOLOME ANALYSIS LABORATORY PRACTICE

  2024

• MASTER SEMINAR

  2024

• INDEPENDENT RESEARCH

  2024

display all >>